Editas Medicine, Inc. — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2021-03-02

Reporting Person: MULLEN JAMES C (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-02	Common Stock	P	25000	$46.272	Acquired	35000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-02	Stock Option (right to buy)	$45.69	A	196637	Acquired	2031-03-01	Common Stock (196637)	Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $46.27 to $46.44. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: This option was granted on March 2, 2021 and is scheduled to vest as to one-third of the shares underlying the option when the closing price of the Issuer's common stock, as reported on the Nasdaq Global Select Market, has for 15 consecutive trading days in the five year period following the grant date equaled or exceeded $80.00, $100.00 and $120.00 per share, respectively.